Titan Announces Completion of Re-Registration of the Company With the Securities and Exchange Commission April 27, 2010
Titan Initiates Confirmatory Phase 3 Study of Probuphine(R) in the Treatment of Opioid Addiction March 30, 2010
Titan Pharmaceuticals Files Form 10 for Re-registration of the Company With the Securities and Exchange Commission January 19, 2010
Titan Receives Notice of Allowance for Probuphine(R) Patent Application in the Treatment of Opiate Addiction November 30, 2009
Novartis Pharma Acquires Exclusive Rights From Vanda Pharmaceuticals for Commercialization of Fanapt(TM) in the United States and Canada October 13, 2009
